Author
Listed:
- Takeshi Imamura
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Masao Takase
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Ayako Nishihara
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Eiichi Oeda
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Jun-ichi Hanai
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Masahiro Kawabata
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
- Kohei Miyazono
(The Cancer Institute, Tokyo, Japanese Foundation for Cancer Research, and Research for the Future Program, Japan Society for the Promotion of Science)
Abstract
SMAD proteins1 have been identified as signalling mediators of the TGF-β superfamily, which is involved in a range of biological activities including cell growth, morphogenesis, development and immune responses2,3. Smad1, Smad2, Smad3 and Smad5 are ligand-specific: Smad1 and Smad5 transduce signals from bone morphogenetic proteins4,5,6,7, and Smad2 and Smad3 mediate signalling by TGF-β and activin8,9, whereas Smad4 acts as a common signalling component10. For example, Smad2 is phosphorylated by the TGF-β type I receptor upon ligand binding, forms a heteromer with Smad4, and then translocates into the nucleus where it activates transcription10,11. Here we report the isolation of Smad6 in the mouse. Smad6 is quite different in structure from the other SMAD proteins, and forms stable associations with type I receptors. Smad6 interferes with the phosphorylation of Smad2 and the subsequent heteromerization with Smad4, but does not inhibit the activity of Smad3. Smad6 also inhibits the phosphorylation of Smad1 that is induced by the bone morphogenetic protein type IB receptor. These data indicate that signals of the TGF-β superfamily are regulated both positively and negatively by members of the SMAD family.
Suggested Citation
Takeshi Imamura & Masao Takase & Ayako Nishihara & Eiichi Oeda & Jun-ichi Hanai & Masahiro Kawabata & Kohei Miyazono, 1997.
"Smad6 inhibits signalling by the TGF-β superfamily,"
Nature, Nature, vol. 389(6651), pages 622-626, October.
Handle:
RePEc:nat:nature:v:389:y:1997:i:6651:d:10.1038_39355
DOI: 10.1038/39355
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:389:y:1997:i:6651:d:10.1038_39355. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.